Actelion (XSWX:ATLNE) Common Stock : CHF54 Mil (As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Actelion Common Stock?

Actelion's quarterly common stock stayed the same from Sep. 2016 (CHF54 Mil) to Dec. 2016 (CHF54 Mil) and stayed the same from Dec. 2016 (CHF54 Mil) to Mar. 2017 (CHF54 Mil).

Actelion's annual common stock stayed the same from Dec. 2014 (CHF57 Mil) to Dec. 2015 (CHF57 Mil) but then declined from Dec. 2015 (CHF57 Mil) to Dec. 2016 (CHF54 Mil).

Actelion Common Stock Historical Data

The historical data trend for Actelion's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Common Stock Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Common Stock

Get a 7-Day Free Trial

63.39

60.14

57.06

53.88

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Common Stock	Get a 7-Day Free Trial															57.06	57.06	53.88	53.88	53.88

Actelion Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Actelion (XSWX:ATLNE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (XSWX:ATLNE) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (XSWX:ATLNE) Headlines

No Headlines